Meds A-Z
Lotilaner
Detailed information about Lotilaner
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies.
What it does:
For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies. For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax...
When it's needed:
For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies.
Commonly reported reactions:
- (2 reports)
- (2 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Lotilaner
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Elanco US Inc.
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/6662 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/6664 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
No contraindication summary is linked yet.
No owner-focused warning rows are linked yet.
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 1 | |
| 2 | Cat, Dog | 0 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (25) Dog (7)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-055691
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 17 • Secondary summaries: 0
- FOI Summary oV 006-662 Authorized October 24, 2025.pdf · FOI
- Credelio™ · SPL
- FOI oV 006-664 Authorized November 21, 2025.pdf · FOI
- Credelio™ CAT · SPL
- FOI Summary o 141-619 Approved December 17, 2025 (2).pdf · FOI
- Credelio Quattro™-CA1 · SPL
- FOI Summary sN 141-494 Approved October 24, 2025.pdf · FOI
- FOI Summary sN 141-494 Approved September 3, 2019.pdf · FOI
- FOI Summary oN 141-494 Approved January 19, 2017.pdf · FOI
- Credelio™ · SPL
- FOI Summary sN 141-581 Approved October 20, 2025.pdf · FOI
- FOI Summary sN 141-581 Approved May 21, 2025.pdf · FOI
- FOI Summary oN 141-581 Approved October 7, 2024.pdf · FOI
- Credelio Quattro™ · SPL
- FOI Summary sN 141-528 Approved April 12, 2021.pdf · FOI
- FOI Summary oN 141-528 Approved December 9, 2019.pdf · FOI
- Credelio™ CAT · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17968 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18328/Credelio%E2%84%A2 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17966 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18326/Credelio%E2%84%A2%20CAT · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17789 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18151/Credelio%20Quattro%E2%84%A2-CA1 · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17693 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/7663 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3101 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2851/Credelio%E2%84%A2 · document · SPL
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:42 PM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 58198-5451-1 | 58198 | - | |
| 58198-5451-2 | 58198 | - | |
| 58198-5451-3 | 58198 | - | |
| 58198-5451-4 | 58198 | - | |
| 58198-5451-6 | 58198 | - | |
| 58198-5451-7 | 58198 | - | |
| 58198-5452-1 | 58198 | - | |
| 58198-5452-2 | 58198 | - | |
| 58198-5452-3 | 58198 | - | |
| 58198-5452-4 | 58198 | - | |
| 58198-5452-5 | 58198 | - | |
| 58198-5452-6 | 58198 | - | |
| 58198-5452-7 | 58198 | - | |
| 58198-5454-1 | 58198 | - | |
| 58198-5454-2 | 58198 | - | |
| 58198-5454-3 | 58198 | - | |
| 58198-5454-4 | 58198 | - | |
| 58198-5454-6 | 58198 | - | |
| 58198-5454-7 | 58198 | - | |
| 58198-5456-1 | 58198 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI oV 006-664 Authorized November 21, 2025.pdf
• FOI summary • Official
• Jan. 26, 2026
FDA FOI summary for application 6664
-
FOI Summary oV 006-662 Authorized October 24, 2025.pdf
• FOI summary • Official
• Jan. 26, 2026
FDA FOI summary for application 6662
-
FOI Summary o 141-619 Approved December 17, 2025 (2).pdf
• FOI summary • Official
• Jan. 5, 2026
FDA FOI summary for application 141619
-
FOI Summary oN 141-581 Approved October 7, 2024.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary sN 141-581 Approved May 21, 2025.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary sN 141-581 Approved October 20, 2025.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary oN 141-494 Approved January 19, 2017.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141494
-
FOI Summary sN 141-494 Approved September 3, 2019.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141494
-
FOI Summary sN 141-494 Approved October 24, 2025.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141494
-
FOI Summary oN 141-528 Approved December 9, 2019.pdf
• FOI summary • Official
• May 3, 2021
FDA FOI summary for application 141528
-
FOI Summary sN 141-528 Approved April 12, 2021.pdf
• FOI summary • Official
• May 3, 2021
FDA FOI summary for application 141528
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- side_effects: Top reported reactions (openFDA): Vomiting, Diarrhoea, Lack of efficacy (ectoparasite) - tick NOS, Other abnormal test result NOS, Lethargy (see also Central n… (Official, 2026-02-12)
- usage: For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies. For the treatment of infestat… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Credelio™
RX
Lotilaner
Chewable Tablets
• Oral
|
Elanco US Inc. | E 6662 | G | Jan 26, 2026 |
|
Credelio™ CAT
RX
Lotilaner
Chewable Tablets
• Oral
|
Elanco US Inc. | E 6664 | G | Jan 26, 2026 |
|
Credelio Quattro™-CA1
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-619 | Approved | Jan 5, 2026 |
|
Credelio™
RX
Lotilaner
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-494 | Approved | Nov 3, 2025 |
|
Credelio Quattro™
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-581 | Approved | Nov 3, 2025 |
|
Credelio™ CAT
RX
Lotilaner
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-528 | Approved | May 3, 2021 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies.
Administer orally at the minimum dosage of 9 mg/lb (20 mg/kg) with food.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens.
Administer orally at the minimum dosage of 2.7 mg/lb (6 mg/kg) with food.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
Administer orally at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Credelio™ kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater. Credelio™ is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
Credelio™ chewable tablets are given orally once a month at the recommended minimum dosage of 9 mg/lb (20 mg/kg). Credelio™ must be administered with food.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Credelio Quattro™ is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro™ kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma Americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater. Credelio Quattro™ is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
Administer orally once a month, at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 pounds or greater. It also indicated for the treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older, and weighing 2.0 pounds or greater.
Administer orally once a month at the minimum dosage of 2.7 mg/lb (6 mg/kg). Must be administered with food.
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies.
- Credelio™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens.
- Credelio™ CAT (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
- Credelio Quattro™-CA1 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) tick infestations for one month in dogs and puppies 8 weeks of age and older, weighing 4.4 pounds or greater, and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
-
Summary
This supplement provides for the addition of the indication for the prevention of flea
infestations (Ctenocephalides felis) for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater. -
Summary
Credelio™ kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater.
- Credelio™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) tick infestations for one month in dogs and puppies 8 weeks of age and older, weighing 3.3 pounds or greater, and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
-
Summary
This supplement provides for the addition of the indication for the treatment and control of hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum) infections in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
- Credelio Quattro™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older, and weighing 2.0 pounds or greater.
-
Summary
Kills adult fleas, and for the treatment and prevention of flea infestation (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 pounds or greater.
- Credelio™ CAT (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in dogs and puppies. For the treatment of infestations caused by New World screwworm ( Cochliomyia hominivorax ) larvae (myiasis) in cats and kittens. Credelio™ kills adult fleas and is indicated for the treatment and prevention of flea infestations ( Ctenocephalides felis ) and the treatment and control of tick infestations [ Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater. Credelio™ is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
No approved contraindication text is linked yet. Review FDA label highlights and openFDA safety reports before making treatment decisions.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Havanese, Male, 12 year, 7.711 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Diarrhea, Inappropriate defecation • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055917
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 12.00 Year
- Weight: 7.711 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Cat, Domestic Shorthair, Male, 9.41 year, 5.724 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Panting, Uncomfortable, Itching • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055819
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 9.41 Year
- Weight: 5.724 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Cat, Siberian, Male, 11 month, 5.352 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Not eating, Tiredness (lethargy), Sleepiness - systemic disorder, Vomiting bile, Increased bowel movements… • Outcome: Died
- Report ID: USA-USFDACVM-2025-US-055971
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 11.00 Month
- Weight: 5.352 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Retriever - Labrador, Female, 1 year, 25.85 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Vomiting • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055920
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 1.00 Year
- Weight: 25.850 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Bulldog - French, Female, 3 year, 15.42 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Cyst NOS, Lack of efficacy (endoparasite) - heartworm • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055991
- Serious AE: No
- Treated For AE: Yes
- Sex: Female
- Age: 3.00 Year
- Weight: 15.420 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Retriever - Golden, Female, 13 week, 6.8 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Vomiting • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-056124
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 13.00 Week
- Weight: 6.800 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Setter (unspecified), Male, 6.91 year, 36.28 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal • Reactions: Vomiting • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055625
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 6.91 Year
- Weight: 36.280 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
Dog, Irish Wolfhound, Male, 6 year, 63.5 kilogram • Drug: MSK, Tablet, chewable, Oral, Dose: 1 tablet per animal, Frequency: 1 per month • Reactions: Lack of efficacy (ectoparasite) - flea • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055993
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 6.00 Year
- Weight: 63.500 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Oral
- Form: Tablet, chewable
- Dose: 1 tablet per animal
- Frequency: 1 per month
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.